Achaogen Inc. traded at $0.03 this Friday June 18th, decreasing $0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Achaogen Inc. lost 6.84 percent. Over the last 12 months, its price rose by 108.33 percent. Looking ahead, we forecast Achaogen Inc. to be priced at 0.02 by the end of this quarter and at 0.02 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Achaogen Inc.
Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of antibacterials to treat multi-drug resistant (MDR), gram-negative infections. It is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). It initiated a Phase III trial of plazomicin in the first quarter of 2014. In addition, to plazomicin, its research and development pipeline includes two programs that specifically target infections caused by Pseudomonas aeruginosa, which it refers to as antipseudomonal programs. The first is a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and the second is a therapeutic antibody program. It is also pursuing small molecule research programs.